Clinical Trial Update: A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ramucirumab or necitumumab plus osimertinib in non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Necitumumab (necitumumab)
• Osimertinib (osimertinib)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-02-05